What is the role of gemtuzumab in the treatment of acute myeloid leukemia (AML) consist of?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


In adults with newly diagnosed de novo CD33-positive AML, combination therapy that includes gemtuzumab consists of one induction and two consolidation cycles, as follows:

  • Gemtuzumab 3 mg/m 2 (up to one 4.5 mg vial) on days 1, 4, and 7 in combination with daunorubicin and cytarabine
  • For patients requiring a second induction cycle, do not administer gemtuzumab in the second induction cycle.

A treatment course of gemtuzumab as a single agent for adults with newly-diagnosed CD33-positive AML consists of the following:

  • Induction – Gemtuzumab 6 mg/m 2 on day 1, then 3 mg/m 2 on day 8, for one cycle
  • Continuation therapy – Gemtuzumab 2 mg/m 2 on day 1 every 4 weeks, for up to eight cycles [11]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!